Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 2: Practical issues and specific cases

Annals of Internal Medicine

Volumn 133, Issue 6, 2000, Pages 464-470

  Ellenberg, S S ^a   Temple, R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL AFFECTING AGENT; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORGANIC NITRATE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RESERPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL STUDY; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG USE; EVALUATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOKALEMIA; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034687076     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-6-200009190-00015     Document Type: Review

References (44)

1. The continuing unethical use of placebo controls
2. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
3. Hazards of inference: The active control investigation
4. Ethical dilemmas in clinical research
5. Re: CCNP position paper on the use of placebos in psychiatry
6. Fluoxetine and suicide A meta-analysis of controlled trials of treatment for depression
7. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database
8. Effects of medical interventions on suicidal behavior. Summary and conclusions
9. Ethical dilemmas in clinical research with human subjects: An investigator's perspective
10. Medication-free research with schizophrenic patients. A European perspective
11. The call of the sirens. Navigating the ethics of medication-free research in schizophrenia
12. Drug-free research in schizophrenia: An overview of the controversy
13. The rational and ethics of medication-free research in schizophrenia
14. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension
15. Tissue plasminogen activator for acute ischemic stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
16. Alteplase not yet proven for acute ischaemic stroke
17. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
18. Defibrinogenation with Vipronex (Ancrod) for the treatment of acute, ischemic stroke STAT Writers Group
19. PROACT II: Recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. PROACT II Investigators
20. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
21. Randomised trial of irinotecan versus fluotouracil by continuous infusion after fluorouracil failure in padents with metastatic colorectal cancer
22. Concorde MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee
23. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer that 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases
24. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group
25. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progerto Pertusse Working Group
26. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell perrussis vaccine
27. Preliminary report Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction The Cardiac Arrhythmia Suppression Trial (CAST) Investigators
28. The effect of digoxin on mortality and morbidity in patients with heart failure The Digitalis Investigation Group
29. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries
30. Unethical trials of interventions to reduce perinaral transmissions of the human immunodeficiency virus in developing countries
31. The ethics of clinical research in the Third World
32. Ethical complexities of conducting research in developing countries
33. Science, ethics, and the future of research into maternal infant transmission of HIV-1 Perinatal HIV. Intervention Research in Developing Countries Workshop participants
34. Ethics and international research
35. Clinical AIDS research that evaluates cost effectiveness in the developing world
36. Placebo controls in HIV perinaral transmission trials: A South African's viewpoint
37. Placebo-controlled studies in rheumatoid arthritis: Ethical issues
38. When are placebo-controlled trials no longer appropriate?
39. The need to revise the Declaration of Helsinki